T cell Isolation from Whole Blood
using 50nm Superparamagnetic IngenuityTM Beads
Simplified, time-saving T cell isolation process directly from Whole Blood
The therapeutic efficacy of chimeric antigen receptor (CAR) T cells in hematologic malignancies underscores the urgency for a cost-effective manufacturing process. T cell isolation, a crucial upstream step, significantly influences T cell quality and therapy success.
Isolating T cells for CAR T cell therapy directly from whole blood, utilizing the MARS® Bar platform and IngenuityTM 50nm beads, offers several advantages:
– it simplifies the process by reducing the number of required manipulations, enhancing efficiency and cost-effectiveness
– saves time by eliminating the need for additional centrifugation and purification steps, crucial in urgent scenarios where fast production of CAR T cells is key.
Isolation of T Cells Directly from Whole Blood
Through the unique capability to directly isolate T cells from whole blood, researchers can reliably achieve the separation of T cells with high purity and yield using the MARS® Bar platform technology.
Panel A shows flow cytometry plot of the Peripheral Whole blood sample prior to separation, Panel B presents the enriched T cells isolated directly from whole blood using IngenuityTM 50nm beads.
Starting with an initial average T cell purity of 21.73%, T cell positive selection using the IngenuityTM 50nm CD4 and CD8 beads on the MARS® Bar system resulted in an average recovery rate of 57.17% T cells with a mean purity of 89.17% (A, n= 4 samples).
Additionally, an evaluation of viability before and after the separation demonstrated no significant impact (P<0.5) on cell viability.
Download the new Application note
Explore other MARS® Platform Applications
Target Cell Isolation
Explore other MARS® Platform Applications
